However, SGLT-2 inhibitors reduced admission to hospital for HF more than GLP-1 receptor agonists, and GLP-1 receptor agonists reduced non-fatal stroke more than SGLT-2 inhibitors (which appeared to have no effect) [67]. The gene discussed is SLC5A2; the disease is stroke disorder.